Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Cancer Res. 2014 Feb 7;74(7):1913–1923. doi: 10.1158/0008-5472.CAN-13-3001

Figure 4.

Figure 4

Pharmacodynamics, tumor retention kinetics and efficacy after anti-DR5-Cy5 treatment. (A) Pharmacodynamic time course of apoptosis induction during therapy. Arrows indicate drug application. (B) Tumor volumes at endpoint of efficacy study. Tumor volumes were determined by 3DISCO of stained tumor vessels in explanted brains; *p < 0.05. (C) Representative 2D virtual sections and related 3-dimensional reconstructed brains showing the location, invasive growth and volume of brain tumors (white-blue) at endpoint of efficacy study. Dimensions of brain tumors were determined by lectin staining. Dashed line: corpus callosum/midline of brain; solid line: outer rim of right brain hemisphere. (D) Apoptosis induction dynamics and tumor retention kinetics of anti-DR5-Cy5 (3 mg/kg i.v.) over 72 hours in brain tumors. 50% decline is marked by dashed lines; n = 5. (E) Apoptosis induction dynamics and tumor retention kinetics of anti-DR5-Cy5 (3 mg/kg i.v.) over 72 hours in s.c. tumors. 50% decline is marked by dashed lines; n = 5.